|
US6500948B1
(en)
|
1995-12-08 |
2002-12-31 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
|
|
IL124559A
(en)
*
|
1995-12-08 |
2004-07-25 |
Agouron Pharma |
Inhibitors of metalloproteinases, pharmaceutical preparations containing them and their use
|
|
FR2748026B1
(fr)
*
|
1996-04-26 |
1998-06-05 |
Adir |
Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
CZ62699A3
(cs)
*
|
1996-08-28 |
1999-07-14 |
The Procter & Gamble Company |
Heterocyklické inhibitory metaloproteinas
|
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US5962481A
(en)
*
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
ATE212619T1
(de)
*
|
1996-10-22 |
2002-02-15 |
Upjohn Co |
Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
|
|
US6008243A
(en)
*
|
1996-10-24 |
1999-12-28 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
|
|
US6174915B1
(en)
|
1997-03-25 |
2001-01-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
|
SG104284A1
(en)
*
|
1996-10-30 |
2004-06-21 |
Tanabe Seiyaku Co |
S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
|
|
ZA98376B
(en)
*
|
1997-01-23 |
1998-07-23 |
Hoffmann La Roche |
Sulfamide-metalloprotease inhibitors
|
|
US6376506B1
(en)
|
1997-01-23 |
2002-04-23 |
Syntex (U.S.A.) Llc |
Sulfamide-metalloprotease inhibitors
|
|
EA002810B1
(ru)
*
|
1997-01-23 |
2002-10-31 |
Ф.Хоффманн-Ля Рош Аг |
Сульфамидные ингибиторы металлопротеаз
|
|
US5985900A
(en)
*
|
1997-04-01 |
1999-11-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
|
DE19719817A1
(de)
*
|
1997-05-13 |
1998-11-19 |
Hoechst Ag |
Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
|
|
CA2297988A1
(en)
*
|
1997-08-04 |
1999-02-11 |
Amgen Inc. |
Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
|
|
ATE242768T1
(de)
*
|
1997-10-06 |
2003-06-15 |
Wyeth Corp |
Herstellung und verwendung von ortho-sulfonamido bicyclische heteroaryl hydroxamsäure derivate als matrix-metalloproteinase und tace inhibitoren
|
|
US6130220A
(en)
*
|
1997-10-16 |
2000-10-10 |
Syntex (Usa) Inc. |
Sulfamide-metalloprotease inhibitors
|
|
FR2771095B1
(fr)
*
|
1997-11-14 |
1999-12-17 |
Adir |
Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US6335329B1
(en)
|
1997-12-19 |
2002-01-01 |
Amgen Inc. |
Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
|
|
US6107291A
(en)
*
|
1997-12-19 |
2000-08-22 |
Amgen Inc. |
Azepine or larger medium ring derivatives and methods of use
|
|
KR20010034406A
(ko)
*
|
1998-01-27 |
2001-04-25 |
아메리칸 사이아나미드 컴파니 |
매트릭스 메탈로프로테인아제 억제제로서의2,3,4,5-테트라하이드로-1ｈ-[1,4]-벤조디아제핀-3-하이드록삼산
|
|
US6071903A
(en)
*
|
1998-01-27 |
2000-06-06 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
|
|
CA2330108A1
(en)
|
1998-05-14 |
1999-11-18 |
Dupont Pharmaceuticals Company |
Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
|
|
AU6228499A
(en)
*
|
1998-10-22 |
2000-05-08 |
Akzo Nobel N.V. |
Tetrahydropyridopyridine derivatives and intermediates for producing the same
|
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6544984B1
(en)
|
1999-01-27 |
2003-04-08 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
|
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
|
AR022423A1
(es)
*
|
1999-01-27 |
2002-09-04 |
American Cyanamid Co |
Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
|
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
EP1147085B1
(en)
|
1999-01-27 |
2005-11-16 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
|
|
US6753337B2
(en)
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
|
US6946473B2
(en)
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
|
GB9903598D0
(en)
*
|
1999-02-18 |
1999-04-07 |
Univ Manchester |
Connective tissue healing
|
|
CO5261615A1
(es)
|
1999-12-01 |
2003-03-31 |
Agouron Pharma |
Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
|
|
GB0011409D0
(en)
*
|
2000-05-11 |
2000-06-28 |
Smithkline Beecham Plc |
Novel compounds
|
|
MXPA01013172A
(es)
*
|
2001-02-14 |
2002-08-21 |
Warner Lambert Co |
Inhibidores sulfonamida de metaloproteinasa de matriz.
|
|
FR2821842B1
(fr)
*
|
2001-03-07 |
2003-05-09 |
Servier Lab |
Nouveaux derives d'inhibiteurs de mettalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
AU2002324716A1
(en)
|
2001-08-17 |
2003-03-03 |
Bristol-Myers Squibb Company Patent Department |
Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
|
|
JP2005507937A
(ja)
|
2001-11-01 |
2005-03-24 |
ワイス・ホールディングズ・コーポレイション |
マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
|
|
RU2223703C2
(ru)
*
|
2002-02-13 |
2004-02-20 |
Иркутский государственный институт усовершенствования врачей |
Способ лечения передней хронической нестабильности коленного сустава
|
|
DE10209299A1
(de)
*
|
2002-03-02 |
2003-09-18 |
Aventis Pharma Gmbh |
Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase
|
|
US6716853B2
(en)
|
2002-03-02 |
2004-04-06 |
Aventis Pharma Deutschland Gmbh |
Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase
|
|
AU2003304456A1
(en)
|
2002-12-23 |
2005-03-16 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
|
|
WO2004060892A1
(ja)
*
|
2002-12-27 |
2004-07-22 |
Japan Tobacco Inc. |
縮合ｎ含有ヘテロ環化合物及びその医薬用途
|
|
DE10300015A1
(de)
*
|
2003-01-03 |
2004-07-15 |
Aventis Pharma Deutschland Gmbh |
Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
|
|
US7205315B2
(en)
|
2003-09-27 |
2007-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
|
|
DE10344936A1
(de)
|
2003-09-27 |
2005-04-21 |
Aventis Pharma Gmbh |
Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
|
|
DE10351904A1
(de)
*
|
2003-11-06 |
2005-06-09 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Herstellung von cyclischen N-substituierten alpha-Iminocarbonsäure
|
|
US7244845B2
(en)
*
|
2003-11-06 |
2007-07-17 |
Sanofi-Aventis Deutschland Gmbh |
Process for preparing cyclic N-substituted alpha-imino carboxylic acids
|
|
DE102004004974A1
(de)
*
|
2004-01-31 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
|
|
WO2005108367A1
(en)
*
|
2004-05-03 |
2005-11-17 |
Envivo Pharmaceuticals, Inc. |
Compounds for treatment of neurodegenerative diseases
|
|
DE102004031850A1
(de)
*
|
2004-06-30 |
2006-01-26 |
Sanofi-Aventis Deutschland Gmbh |
Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
|
|
DE102004031620A1
(de)
*
|
2004-06-30 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
|
|
US7601838B2
(en)
*
|
2004-12-28 |
2009-10-13 |
Council Of Scientific And Industrial Research |
2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
|
|
DE102005002500A1
(de)
|
2005-01-19 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
|
|
DE102005015040A1
(de)
|
2005-03-31 |
2006-10-05 |
Sanofi-Aventis Deutschland Gmbh |
Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
|
|
ZA200710313B
(en)
|
2005-05-13 |
2009-05-27 |
Topotarget Uk Ltd |
Pharmaceutical formulations of HDAC inhibitors
|
|
JP2009512844A
(ja)
*
|
2005-10-20 |
2009-03-26 |
ノルディック・バイオサイエンス・ダイアグノスティクス・アクティーゼルスカブ |
アグリカンおよびそのフラグメントの検出または定量
|
|
GB0526257D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
US20100226922A1
(en)
*
|
2006-06-08 |
2010-09-09 |
Dorothea Maetzel |
Specific protease inhibitors and their use in cancer therapy
|
|
EP2182810B1
(en)
|
2007-08-03 |
2017-11-08 |
Nucitec S.A. de C.V. |
Compositions and methods for treatment and prevention of osteoarthritis
|
|
WO2009019286A1
(en)
|
2007-08-07 |
2009-02-12 |
Abbott Gmbh & Co. Kg |
Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
|
CA2709383A1
(en)
|
2007-12-14 |
2009-06-25 |
Milton L. Brown |
Histone deacetylase inhibitors
|
|
ES2527589T3
(es)
*
|
2008-04-24 |
2015-01-27 |
Msd K.K. |
Inhibidor de la enzima de elongación de ácidos grasos de cadena larga que comprende un derivado de arilsulfonilo como principio activo
|
|
EP2318361B1
(en)
|
2008-07-14 |
2015-09-23 |
Novartis AG |
Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
|
|
FR2947268B1
(fr)
|
2009-06-30 |
2011-08-26 |
Galderma Res & Dev |
Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
|
|
FR2947270B1
(fr)
|
2009-06-30 |
2011-08-26 |
Galderma Res & Dev |
Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
|
|
US20140275108A1
(en)
|
2013-03-15 |
2014-09-18 |
Galderma Research & Development |
Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
|
|
WO2017117130A1
(en)
|
2015-12-28 |
2017-07-06 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
|
|
EP3199534B1
(en)
|
2016-02-01 |
2018-09-05 |
Galderma Research & Development |
Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
|
|
RU2748835C1
(ru)
|
2017-11-27 |
2021-05-31 |
Совет Научных И Прикладных Исследований |
Индол(сульфонил)-n-гидроксибензамидные производные в качестве селективных ингибиторов hdac
|
|
WO2025224168A1
(en)
|
2024-04-24 |
2025-10-30 |
Idorsia Pharmaceuticals Ltd |
Aryl sulfone and sulfanone derivatives as orexin receptor modulators
|
|
CN119565781B
(zh)
*
|
2024-12-20 |
2026-01-02 |
中南大学 |
一种金属离子-含氮芳杂环配合物捕收剂及其制备方法和在钨矿浮选中的应用
|